DekaBank Deutsche Girozentrale Decreases Position in Henry Schein, Inc. (NASDAQ:HSIC)

DekaBank Deutsche Girozentrale lessened its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 12.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 843,522 shares of the company’s stock after selling 117,639 shares during the period. DekaBank Deutsche Girozentrale owned approximately 0.66% of Henry Schein worth $54,065,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Nuance Investments LLC lifted its holdings in shares of Henry Schein by 6.2% during the 2nd quarter. Nuance Investments LLC now owns 1,863,333 shares of the company’s stock valued at $119,440,000 after purchasing an additional 108,143 shares during the last quarter. American Century Companies Inc. increased its position in shares of Henry Schein by 3.1% in the 2nd quarter. American Century Companies Inc. now owns 5,484,286 shares of the company’s stock valued at $351,543,000 after acquiring an additional 162,477 shares during the period. Studio Investment Management LLC increased its position in shares of Henry Schein by 4.7% in the 2nd quarter. Studio Investment Management LLC now owns 4,502 shares of the company’s stock valued at $289,000 after acquiring an additional 204 shares during the period. Headlands Technologies LLC increased its position in shares of Henry Schein by 835.4% in the 2nd quarter. Headlands Technologies LLC now owns 8,288 shares of the company’s stock valued at $531,000 after acquiring an additional 7,402 shares during the period. Finally, Daiwa Securities Group Inc. increased its position in shares of Henry Schein by 9.1% in the 2nd quarter. Daiwa Securities Group Inc. now owns 14,040 shares of the company’s stock valued at $900,000 after acquiring an additional 1,171 shares during the period. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Trading Up 3.2 %

Shares of Henry Schein stock opened at $70.38 on Friday. The firm has a market capitalization of $8.92 billion, a PE ratio of 23.78, a P/E/G ratio of 1.88 and a beta of 0.86. Henry Schein, Inc. has a twelve month low of $60.01 and a twelve month high of $82.63. The firm’s 50-day moving average price is $69.11 and its 200 day moving average price is $70.64. The company has a current ratio of 1.55, a quick ratio of 0.90 and a debt-to-equity ratio of 0.46.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.01. The firm had revenue of $3.10 billion for the quarter, compared to analyst estimates of $3.27 billion. Henry Schein had a net margin of 2.82% and a return on equity of 13.19%. Henry Schein’s quarterly revenue was up .0% compared to the same quarter last year. During the same period last year, the company posted $1.31 EPS. On average, sell-side analysts predict that Henry Schein, Inc. will post 4.75 EPS for the current fiscal year.

Insiders Place Their Bets

In other Henry Schein news, SVP Lorelei Mcglynn sold 21,035 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $69.30, for a total value of $1,457,725.50. Following the transaction, the senior vice president now directly owns 71,833 shares of the company’s stock, valued at approximately $4,978,026.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.14% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Baird R W raised Henry Schein from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 22nd. JPMorgan Chase & Co. cut their price target on Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Barrington Research dropped their target price on Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Piper Sandler restated an “overweight” rating and set a $86.00 target price on shares of Henry Schein in a research report on Friday, June 21st. Finally, Evercore ISI dropped their target price on Henry Schein from $72.00 to $70.00 and set an “in-line” rating on the stock in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, six have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $77.10.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.